Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(19):1462-1466; doi:10.1093/jnci/djg057
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (36)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by van der Cruijsen-Koeter, I. W.
Right arrow Articles by Schröder, F. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Cruijsen-Koeter, I. W.
Right arrow Articles by Schröder, F. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

ARTICLE

Interval Carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)–Rotterdam

Ingrid W. van der Cruijsen-Koeter, T. H. van der Kwast, Fritz H. Schröder

Affiliations of authors: I. W. van der Cruijsen-Koeter, F. H. Schröder (Department of Urology), T. H. van der Kwast (Department of Pathology), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Correspondence to: Fritz H. Schröder, MD, PhD, Department of Urology, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands (e-mail: e.vandenberg{at}erasmusmc.nl).

Background: The interval cancer rate is an important parameter for determining the sensitivity of a screening procedure and the screening interval. We evaluated the time and mechanism of detection and the stage distribution of interval prostate cancers diagnosed during a 4-year screening interval. Methods: We determined the rate of interval cancers and the sensitivity of the screening protocol (involving prostate-specific antigen, digital rectal and transrectal ultrasound examinations) in a cohort of 17 226 men (8350 on the screened arm, 8876 on the control arm) enrolled consecutively on the European Randomized Study of Screening for Prostate Cancer–Rotterdam. Men on the screened arm received a first screen between October 1993 and December 1996 and a scheduled second screen 4 years later. Prostate cancers detected in men enrolled on the control arm over the same 4-year period and, between screens, in men on the screened arm, were identified by linkage to the Dutch national cancer registry. Results: During the first screen, 412 prostate cancers were detected. During the subsequent 4-year period, 135 cancers were diagnosed in men in the control arm and 25 cancers were diagnosed in men in the screened arm. Seven of the 25 cancers were diagnosed in men who had refused a recommended biopsy at their initial screen. Of the remaining 18 cancers, all were classified as stage T1A–C or T2A and none were poorly differentiated or metastatic. The rate of interval cancers relative to the number of cancers in the control group was 18.5% (25/135), or 13.3% (18/135), if the seven who refused an initial biopsy were excluded. The sensitivity of the screening protocol was 79.8% when considering all 25 interval cancers and 85.5% when considering 18 interval cancers. Conclusion: The interval cancer rate with a 4-year screening interval was low, confirming that the screening procedure has a high sensitivity and that the 4-year screening interval is reasonable.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
C. Hamashima, T. Nakayama, M. Sagawa, H. Saito, and T. Sobue
The Japanese Guideline for Prostate Cancer Screening
Jpn. J. Clin. Oncol., June 1, 2009; 39(6): 339 - 351.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. J. Roobol and F. H. Schroder
Re: Is a Screening Interval of Every 4 Years for Prostate Cancer Acceptable?
J Natl Cancer Inst, February 6, 2008; 100(3): 222 - 222.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. B. Carter, L. Ferrucci, A. Kettermann, P. Landis, J. Wright, J. I. Epstein, B. J. Trock, and E. J. Metter
Response: Re: Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability
J Natl Cancer Inst, March 21, 2007; 99(6): 490 - 490.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. A. M. J. L. Janssen, M. F. Wildhagen, K. Ito, B. G. Blijenberg, R. H. N. van Schaik, M. J. Roobol, H. A. P. Pols, S. W. J. Lamberts, and F. H. Schroder
Circulating Free Insulin-Like Growth Factor (IGF)-I , Total IGF-I, and IGF Binding Protein-3 Levels Do Not Predict the Future Risk to Develop Prostate Cancer: Results of a Case-Control Study Involving 201 Patients within a Population-Based Screening with a 4-Year Interval
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4391 - 4396.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Makinen, T. L. J. Tammela, U.-H. Stenman, L. Maattanen, J. Aro, H. Juusela, P. Martikainen, M. Hakama, and A. Auvinen
Second Round Results of the Finnish Population-Based Prostate Cancer Screening Trial
Clin. Cancer Res., April 1, 2004; 10(7): 2231 - 2236.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.